Business Wire

Airtel Tanzania Launches International Payments with WorldRemit

Share

Airtel Tanzania has collaborated with WorldRemit, the global payments company to enable Airtel Money customers to send and receive money directly into their Airtel Money wallets from abroad. Airtel Money customers can receive money from over 50 countries worldwide including a number of countries including the United States, United Kingdom, Australia, Sweden, Canada, Germany, Norway, Netherlands, Denmark and Belgium. This will contribute to deepening financial inclusion and further boosting the economic and industrial agenda.

Speaking in Dar es Salaam today to announce the new move, Airtel Tanzania Director of Airtel Money services Isack Nchuda said, “The partnership with WorldRemit will widen access to money transfer for recipients in urban and rural areas of Tanzania as they can now receive international money transfers directly to their mobile wallets without the need for a bank account or internet connection. Our work with WorldRemit will hugely contribute to accomplishing our vision of providing unique, convenient and affordable products and services to our customers. The launch of this service between WorldRemit and Airtel Money is a testimony of our commitment to supporting the ongoing agenda of financial inclusion initiatives and breaking the divide between rural and urban communities.”

WorldRemit makes it easy to send money to Airtel accounts in Tanzania from more than 50 countries around the world. Customers can download the app or create an account to start transferring money to family and friends in Tanzania today.

“We are delighted to be working with Airtel Tanzania to ensure that Tanzanians can have access to financial support from their family and friends abroad. The connection allows us to give customers even more remittance options whilst continuing to provide a convenient, safe and secure service,” said Cynthia Ponera, Country Manager for Tanzania at WorldRemit.

Airtel Tanzania Director of Communication Beatrice Singano said, “Airtel Money is increasingly becoming an attractive and more inclusive operator, in offering faster, convenient and safe, cross border remittances. The service is affordable with the most competitive fees in comparison to other international money transfer corridors. Recipients in Tanzania from over 50 countries will receive their money instantly, once the transaction is confirmed”.

Mobile money has already helped to reduce transaction costs, increase convenience and improve accessibility for individuals and businesses. Recipients no longer need to travel long distances to bank branches to collect their money in person. The Airtel Money and WorldRemit partnership will extend the usage of the Airtel Money wallets to global digital payments.

Airtel Money Tanzania is currently connected to over 1000 companies including utility service providers and is also integrated with over 40 financial institutions. In addition, Airtel Tanzania is rapidly expanding across the country with more than 1200 Airtel Money branches providing all Airtel services and products at all times.

Ends

About WorldRemit

WorldRemit is a leading international payments company. We disrupted an industry previously dominated by offline legacy players by taking international money transfers online - making them safer, faster and lower-cost. We currently send from over 50 to 150 countries, operate in 6,500 money transfer corridors worldwide and employ over 1,100 people worldwide

On the sending side WorldRemit is 100% digital (cashless), increasing convenience and enhancing security. For those receiving money, the company offers a wide range of options including bank deposit, cash collection, mobile airtime top-up and mobile money.

Backed by Accel, TCV and Leapfrog – WorldRemit’s headquarters are in London, United Kingdom with regional offices in the United States, Canada, Australia, New Zealand, Hong Kong, Singapore, Malaysia, the Philippines, South Africa, Somaliland, Uganda, Kenya, Rwanda, Tanzania, Zimbabwe and Belgium.

For more information visit www.worldremit.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media inquiries:
Genevieve Dowokpor
PR Lead EMEA
gdowokpor@worldremit.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release

Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye